Company intelligence / Profile preview

Beijing Beasky Biotechnology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Beasky Biotechnology is a clinical-stage biopharmaceutical company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. The company's lead program, BST02, is a cryopreserved TIL product designed for the treatment of liver cancer, which has received IND clearance from both the FDA and NMPA. Beasky utilizes a proprietary technology platform to optimize the expansion and fitness of TILs, aiming to address the high unmet medical need in advanced solid malignancies. The company is headquartered in Beijing and is supported by prominent venture capital investors.

Therapeutic areas: Oncology
Modalities: Cell therapyTumor-infiltrating lymphocyte therapy
Industry: Biotech

Beyond the preview

Go deeper on Beijing Beasky Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Beasky Biotechnology.

Explore the full profile